CDKN2BAS rs1011970: Understanding Breast Cancer Risk Associations
The genetic variant rs1011970 is a single nucleotide polymorphism located within the CDKN2BAS gene region. Research has identified this variant as being associated with a genetic predisposition to breast cancer, specifically showing links to breast cancer in situ.
What each genotype means
Baseline breast cancer risk
This genotype represents the non-risk version of this variant. Individuals with this profile do not carry the specific genetic marker associated with the increased breast cancer susceptibility identified in genome-wide association studies.
This is the most common genotype for this variant across most global populations.
Slightly increased breast cancer risk
Carrying one copy of the T allele is associated with a statistically significant, though modest, increase in the risk of developing breast cancer compared to those without the variant. This association has been observed in large-scale studies, though individual risk is influenced by many other genetic and environmental factors.
This heterozygous genotype is found in a significant portion of the population, reflecting the common nature of this variant.
Increased breast cancer risk
Carrying two copies of the T allele is associated with a higher statistical predisposition to breast cancer compared to the GG genotype. Research indicates this variant may be specifically linked to a stronger predisposition to breast cancer in situ, though this does not constitute a medical diagnosis or a certainty of disease development.
This homozygous genotype is less common than the GG or GT genotypes but is present across diverse ancestral groups.
What is rs1011970?
The variant rs1011970 is a single nucleotide polymorphism (SNP) found on chromosome 9. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is situated within the CDKN2BAS gene, which is also known as CDKN2B-AS1. This region of the genome is of interest to researchers because it contains regulatory elements that may influence how nearby genes are expressed. By studying these variations, scientists aim to understand the complex genetic architecture that contributes to various health conditions, including cancer susceptibility. Because rs1011970 is a common variant, it is frequently included in large-scale genome-wide association studies (GWAS) designed to map the genetic landscape of human disease.
The Role of CDKN2BAS
The CDKN2BAS gene, or CDKN2B antisense RNA 1, is a long non-coding RNA (lncRNA). Unlike protein-coding genes that provide instructions for building proteins, lncRNAs often function by regulating the activity of other genes. CDKN2BAS is located in a critical genomic region that also houses the CDKN2A and CDKN2B genes, which are well-known tumor suppressors involved in cell cycle regulation. By acting as a regulator, the CDKN2BAS transcript may influence the expression of these neighboring tumor-suppressing genes. Disruptions or variations in this regulatory region can potentially alter the cell's ability to control growth and division, which are fundamental processes in the development of cancer. Research into this gene continues to evolve as scientists work to clarify the precise mechanisms by which it influences cellular health.
Research and Evidence Strength
The association between rs1011970 and breast cancer has been identified through genome-wide association studies. These studies compare the genomes of individuals with a specific condition to those without it to find statistical correlations. Evidence suggests that this variant is associated with a predisposition to breast cancer, with some research highlighting a stronger link to breast cancer in situ compared to invasive forms of the disease. It is important to note that the evidence strength for this association is considered moderate. Genetic predisposition is rarely the sole cause of cancer; rather, it is one of many factors, including environmental exposures, lifestyle, and other genetic markers, that contribute to overall risk. Because these associations are statistical in nature, they describe population-level trends rather than individual outcomes.
Population Frequency
The rs1011970 variant is considered common across various human populations. In genetic research, a variant is typically classified as common if it appears with a significant frequency in the general population. Data from large-scale genomic databases, such as gnomAD, indicate that the T allele is present at a notable frequency, allowing researchers to study its effects across diverse ancestral groups. Understanding the frequency of a variant is essential for determining its potential impact on public health. While the variant is common, its presence does not guarantee the development of any condition. Instead, it serves as a marker that researchers use to better understand the biological pathways involved in breast cancer development.
Interpreting Genetic Information
Information regarding genetic variants like rs1011970 is intended for educational purposes and should not be used for medical diagnosis or personal health decisions. Genetic associations are complex and often involve interactions between multiple genes and environmental factors. If you are concerned about your personal risk for breast cancer, it is essential to consult with a healthcare professional or a genetic counselor. They can provide context based on your personal and family medical history, which is far more predictive than any single genetic variant. You should never use information from genetic databases to make changes to your medical care or screening schedule. Always discuss any questions about your health or genetic testing results with a qualified clinician who can provide personalized guidance.
How common is this variant?
The rs1011970 variant is a common polymorphism found across diverse ancestral populations, with a global minor allele frequency of approximately 0.22.
Frequently asked questions
Does having the T allele mean I will get breast cancer?
No, having the T allele does not mean you will develop breast cancer. Genetic variants are only one of many factors that influence cancer risk, and most people with this variant will never develop the disease.
Can I use this information to change my cancer screening?
No, you should not change your medical screening based on this information. Always follow the screening guidelines recommended by your doctor based on your personal and family health history.
What is the difference between in situ and invasive breast cancer?
Breast cancer in situ refers to abnormal cells that have not spread beyond the original site, while invasive breast cancer has the potential to spread to surrounding tissues. Research into rs1011970 has looked at its specific association with these different tumor characteristics.
Where can I find more information about my personal genetic risk?
If you are interested in your personal risk, you should speak with a certified genetic counselor or your primary care physician. They can help you interpret your family history and determine if clinical genetic testing is appropriate for you.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1011970?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29